ESMO Breast Cancer Congress 2023
The ESMO Breast Cancer Congress 2023, will be held onsite in Berlin, Germany, and online, through a virtual platform, between 11-13 May 2023
ESMO Media Releases
Latest Data Indicate New Care Standard in Advanced/Recurrent Endometrial Cancer: Results from the RUBY Trial
Adding immunotherapy to standard chemotherapy for first-line treatment of advanced or first recurrence of endometrial cancer significantly improves progression-free survival (PFS) compared to chemotherapy alone, with a promising early indication of improved overall survival (OS)
ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European Lung Cancer Congress
ESMO is pleased to announce a combination of brand-new and well-established events happening in March, tackling two specific areas of oncology, with leading experts discussing novel clinical data and the latest treatment options
Death Rates from Lung Cancer will Fall Overall in the EU and UK in 2023, but Rise Among Women in France, Italy and Spain
A total of 1,261,990 people will die from cancer in 2023 in the EU (EU-27). A further 172,314 people will die from the disease in the UK, according to new research published in the leading cancer journal Annals of Oncology today
ESMO Targeted Anticancer Therapies Congress 2023
The ESMO Targeted Anticancer Therapies Congress 2023, the gathering focusing on promising new anticancer targets and agents, with a particular emphasis on those in early phase clinical development, will be held in Paris, France, on 6-8 March 2023.
ESMO Gynaecological Cancers Congress 2023
The ESMO Gynaecological Cancers Congress 2023, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide an overview of the latest treatments as well as insights into the biology and biomarkers of ovarian, uterine, cervical and even rare gynaecological cancers.
Novel Checklist for Quality of Life to Bring ESMO-MCBS and Clinical Trials to the Next Level
The European Society for Medical Oncology (ESMO) has developed a quality of life (QoL) checklist that is now integral to the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) - a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
ESMO Immuno-Oncology Congress 2022, 7-9 December, Geneva, Switzerland
The ESMO Immuno-Oncology Congress 2022, an annual congress dedicated to the presentation and discussion of the latest scientific developments in this fast-moving field, will be held in person in Geneva, Switzerland, and virtually between 7-9 December.
Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate Cancer Development and Treatment, Research Shows
More than 1.4 million men were diagnosed with prostate cancer in 2020 globally but the molecular characteristics of the disease remain unexplored for the majority of patients around the world.
ESMO Asia Congress 2022, 2-4 December 2022
The ESMO Asia Congress 2022 will be held in person in Singapore and virtually between 2-4 December 2022.
Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam, Netherlands
The Molecular Analysis for Precision Oncology Congress 2022 (MAP) is the yearly appointment where leading experts discuss current and future challenges in the rapidly developing field of precision oncology, with the aim of identifying targetable alterations through molecular profiling, to provide the best possible personalised treatment.
A New Era of Early Cancer Detection With Blood Test May Change Cancer Screening Paradigms
Cancer doctors, care providers and payers need to get ready for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment